.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Healthtrust
Colorcon
Fuji
Queensland Health
Baxter
Federal Trade Commission
McKinsey
Cantor Fitzgerald
Harvard Business School

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,006,224

« Back to Dashboard

Which drugs does patent 9,006,224 protect, and when does it expire?


Patent 9,006,224 protects AFINITOR and is included in one NDA. There have been two Paragraph IV challenges on Afinitor.

This patent has forty-one patent family members in twenty-three countries.

Summary for Patent: 9,006,224

Title:Neuroendocrine tumor treatment
Abstract: A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.
Inventor(s): Marks; Peter Wayne (Woodbridge, CT), Lebwohl; David (Madison, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:12/094,173
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
NovartisAFINITOReverolimusTABLET;ORAL022334-003Jul 9, 2010RXYesNo► Subscribe► SubscribeTREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC► Subscribe
NovartisAFINITOReverolimusTABLET;ORAL022334-001Mar 30, 2009RXYesNo► Subscribe► SubscribeTREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC► Subscribe
NovartisAFINITOReverolimusTABLET;ORAL022334-004Mar 30, 2012RXYesNo► Subscribe► SubscribeTREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC► Subscribe
NovartisAFINITOReverolimusTABLET;ORAL022334-002Mar 30, 2009RXYesYes► Subscribe► SubscribeTREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,006,224

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0523658.3Nov 21, 2005
United Kingdom0601082.1Jan 19, 2006
United Kingdom0602747.8Feb 10, 2006
United Kingdom0607942.0Apr 21, 2006
United Kingdom0609272.0May 10, 2006
United Kingdom0609912.1May 18, 2006
06120660Sep 14, 2006
PCT Information
PCT FiledNovember 20, 2006PCT Application Number:PCT/EP2006/068656
PCT Publication Date:May 24, 2007PCT Publication Number: WO2007/057457

International Patent Family for Patent: 9,006,224

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand622710► Subscribe
New Zealand604127► Subscribe
New Zealand568182► Subscribe
Norway20170956► Subscribe
Norway20082683► Subscribe
Norway341023► Subscribe
Norway20161045► Subscribe
Morocco29966► Subscribe
South Korea20140012218► Subscribe
South Korea20080071600► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Chubb
Boehringer Ingelheim
Fuji
Healthtrust
AstraZeneca
Express Scripts
Harvard Business School
Cipla
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot